Richard M. Stone, MD, Dana-Farber Cancer Institute

Articles by Richard M. Stone, MD, Dana-Farber Cancer Institute

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

March 4th 2021

Evolving Field of Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

March 4th 2021

Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 25th 2021

CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 25th 2021

CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 18th 2021

Approach to Managing Relapsed Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 18th 2021

Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 11th 2021

Managing MRD-Negative Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 11th 2021

Managing MRD-Positive Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 4th 2021

Treatment of Acute Lymphoblastic Leukemia in the Community Setting

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 4th 2021

Role of MRD Testing in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 28th 2021

Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 28th 2021

Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 21st 2021

Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

Prognostic Factors Which Impact ALL Management

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

Latest Updated Articles

CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia
February 25th 2021
Approach to Managing Relapsed Acute Lymphoblastic Leukemia
February 18th 2021
Managing MRD-Positive Acute Lymphoblastic Leukemia
February 4th 2021
Role of MRD Testing in Acute Lymphoblastic Leukemia
January 28th 2021
Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia
February 25th 2021
CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia
February 18th 2021

Trending on OncLive

FDA Receives BLA for Etentamig in R/R Multiple Myeloma

Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos

T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer

Elranatamab Meets Phase 3 PFS End Point in R/R Myeloma After Anti-CD38 Therapy and Lenalidomide

Basser Center for BRCA Awards 2026 Global Prize to Judy Garber